Pulse Biosciences Q2 2022 Earnings Report
Key Takeaways
Pulse Biosciences reported revenue of $265 thousand for the second quarter of 2022. The company's GAAP net loss was $14.0 million, while non-GAAP net loss was $11.9 million. They transitioned their commercial focus toward driving utilization of CellFX Systems in a select group of dermatology clinics.
Continued active engagement and collaboration with the nine commercial clinics participating in the CellFX System utilization program.
Received FDA 510(k) clearance of expanded energy settings for use with the family of CellFX System treatment tips in dermatology.
Generated second quarter 2022 revenue of $265 thousand.
Completed two commercial sales of CellFX Systems in the second quarter of 2022.
Pulse Biosciences
Pulse Biosciences
Forward Guidance
Pulse Biosciences is focused on driving utilization of CellFX Systems and expanding indications for the CellFX System.